GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 ... - Benzinga

3 days ago · GSK reported Q4 sales of $10.40B, surpassing estimates of $9.58B, while core EPS of $0.59 beat the consensus of $0.43 despite a 10% decline. Vaccine sales fell 14% to …

CouponFollow Extension

10%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 ... - Benzinga

2 weeks from now

3 days ago · GSK reported Q4 sales of $10.40B, surpassing estimates of $9.58B, while core EPS of $0.59 beat the consensus of $0.43 despite a 10% decline. Vaccine sales fell 14% to …

benzinga.com

14%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion …

2 weeks from now

3 days ago · GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. ... Benzinga Inspire. GSK Q4 Earnings: Revenue And EPS Beat, …

benzinga.com

1%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion …

2 weeks from now

3 days ago · Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The …

yahoo.com

6%
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After Stellar ...

2 weeks from now

3 days ago · GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion …

reuters.com

$2
OFF

GSK Stock Jumps On Long-Term Outlook Boost, $2.5B Share …

2 weeks from now

2 days ago · Its 23.2 pence ($0.29) core earnings per share (EPS) for the fourth quarter and revenue of 8.12 billion pounds also beat estimates. GSK's U.S.-listed shares were up around …

investopedia.com

32%
OFF

GSK (GSK) Tops Q4 Earnings And Revenue Estimates

2 weeks from now

3 days ago · Glaxo (GSK) delivered earnings and revenue surprises of 11.32% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies …

zacks.com

8%
OFF

GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50

2 weeks from now

2 days ago · GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion ... Benzinga. Align Technology …

yahoo.com

8%
OFF

GSK Beats On Q4 Earnings & Sales, Stock Up On Raised Long-Term …

2 weeks from now

3 days ago · GSK expects both core operating profit and core EPS to grow in the range of 6-8%. Our Take on GSK’s Results GSK’s fourth-quarter results were impressive, with both earnings …

nasdaq.com

8%
OFF

GSK Beats On Q4 Earnings & Sales, Stock Up On Raised Long-Term …

2 weeks from now

3 days ago · GSK expects both core operating profit and core EPS to grow in the range of 6-8%. Our Take on GSK’s Results GSK’s fourth-quarter results were impressive, with both earnings …

zacks.com

$0.59
OFF

GSK (GSK) Tops Q4 Earnings And Revenue Estimates - MSN

2 weeks from now

GSK (GSK) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.72 per share a year ago. These …

msn.com

$0.64
OFF

GSK (GSK) Q4 Earnings And Revenues Top Estimates - Nasdaq

2 weeks from now

Feb 1, 2023 · GSK (GSK) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.86 per share a year …

nasdaq.com

1%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5

2 weeks from now

Wednesday, GSK Plc (NYSE: GSK ) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant GSK Q4 Earnings: Revenue …

newsbreak.com

10%
OFF

Regeneron Pharma Q4 Earnings Crush Estimates, Initiates

2 weeks from now

3 days ago · Regeneron posted Q4 adjusted EPS of $12.07, beating the $11.29 consensus. Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew …

benzinga.com

$2
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion …

2 weeks from now

3 days ago · Wednesday,GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.... GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises …

sahmcapital.com

FAQs about GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 ... - Benzinga Coupon?

What was GSK's fourth-quarter sales?

Wednesday, GSK Plc (NYSE: GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 billion. ...

How many times has Glaxo surpassed consensus EPS estimates?

Over the last four quarters, the company has surpassed consensus EPS estimates four times. Glaxo, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $10.4 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.04%. This compares to year-ago revenues of $10 billion. ...

What is the consensus EPS estimate for the coming quarters?

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.89 on $8.39 billion in revenues for the coming quarter and $3.42 on $34.1 billion in revenues for the current fiscal year. ...

What is the consensus EPS estimate?

The current consensus EPS estimate is $1.11 on $9.67 billion in revenues for the coming quarter and $4.07 on $40.5 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. ...

Why did arexvy & abrysvo's revenue fall?

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use. It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024. Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. ...

What are the estimate revisions trend for Glaxo (Glaxo)?

Ahead of this earnings release, the estimate revisions trend for Glaxo: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. ...